Longevity & Aging
Is ageing a treatable disease?
The claim, precisely: aging is a treatable disease
Strong support Longevity & Aging
RefutedContestedStrong support
consensus score 0.77
A viewpoint some researchers argue, not a proven fact — and only tested in cells and animals so far.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Population patterns (Observational)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
11 support 0 contradict 0 tested null 2 mixed · 13 sources, 10 independent groups
What the evidence shows
A strategic/regulatory STANCE (geroscience position papers), not an empirical finding. Recorded as a framing claim, deliberately low-weight.
The evidence (13)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Strong 2016 · Aging Cell | animal | supports | high | NIA ITP: 17-a-estradiol, acarbose, NDGA, Protandim extended mouse lifespan; pharmacologically modifiable aging in mammals (sex/dose dependent) |
| Mohammed 2021 · Front Endocrinol | observational | mixed | moderate | Critical review concludes metformin lifespan-extension evidence remains controversial, not protective in disease-free subjects - tempers treatability claim |
| Wissler Gerdes 2021 · Mech Ageing Dev | mechanism | supports | moderate | Reviews senolytic trial strategy; reports D+Q reduced senescent-cell burden in diabetic-kidney patients + IPF function gain - target-engagement, not hard outcomes |
| Peng 2026 · J Chin Med Assoc | mechanism | supports | moderate | Geromedicine review: WHO ICD-11 MG2A code + FDA-accepted TAME trial framed as institutional milestones for treating aging as multidisease outcome |
| Buch 2026 · Transpl Int | mechanism | supports | low | Argues senescence (an aging hallmark) is a modifiable, assessable target in organ transplantation - independent group applying treatability thesis |
| Justice 2019 · EBioMedicine | observational | supports | low | First-in-human open-label senolytic (D+Q) pilot in IPF improved physical function/mobility - early proof aging mechanism is druggable; n=14 uncontrolled |
| López-Otín 2023 · Cell | mechanism | supports | high | Twelve hallmarks framework: explicit premise that therapeutic intervention on hallmarks can decelerate/reverse aging - the treatability thesis stated, not proven |
| Xiang 2026 · MedComm | mechanism | mixed | low | Reviews mitochondria-targeted anti-aging strategies but stresses translation obstacles/tissue heterogeneity blocking clinical aging treatment |
| Kulkarni 2022 · Aging Cell | mechanism | supports | moderate | Proposes formal process to repurpose FDA drugs targeting aging biology to delay multiple chronic diseases; advocacy/framework not outcome data |
| Khaltourina 2020 · Mech Ageing Dev | mechanism | supports | low | [FT-verified] Khaltourina 2020 ICD-11-criteria argument; framing not empirical |
| Zhavoronkov 2015 · Front Genet | mechanism | supports | low | [FT-verified] Zhavoronkov 2015 ICD-11 framing argument; archived; advocacy not finding |
| Bulterijs 2015 · Front Genet | mechanism | supports | low | [FT-verified] Bulterijs 2015 Frontiers Opinion advocacy/framing not empirical; archived; low-weight correct |
| Rehman 2025 · Cancers (Basel) | mechanism | supports | low | Metformin reframed as prototype gerotherapeutic; cites TAME/biological-age reversal claims - advocacy review, evidence not from controlled aging endpoint |
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.